Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial.

Date publication

mai 2024

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain

Tous les auteurs :
Ah-Thiane L, Campion L, Allouache N, Meyer E, Pommier P, Mesgouez-Nebout N, Serre AA, Créhange G, Guimas V, Rio E, Sargos P, Ladoire S, Mahier Ait Oukhatar C, Supiot S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38734543

Résumé

The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy.

Mots clés

Abiraterone acetate, Biochemical recurrence, Biomarkers, Circulating tumor cells, Hormone therapy, Prostate bed radiotherapy, Prostate cancer, Salvage radiotherapy

Référence

Eur Urol Oncol. 2024 05 10;: